Moderna, Inc. (NASDAQ:MRNA) Shares Acquired by Privium Fund Management B.V.

Privium Fund Management B.V. lifted its holdings in shares of Moderna, Inc. (NASDAQ:MRNA) by 103.7% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 82,476 shares of the company’s stock after buying an additional 41,994 shares during the period. Moderna accounts for approximately 0.8% of Privium Fund Management B.V.’s holdings, making the stock its 23rd biggest position. Privium Fund Management B.V.’s holdings in Moderna were worth $3,429,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Wilmington Savings Fund Society FSB boosted its stake in Moderna by 295.0% in the fourth quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock valued at $33,000 after acquiring an additional 587 shares during the period. Compass Planning Associates Inc acquired a new position in Moderna during the 4th quarter valued at approximately $37,000. Venturi Wealth Management LLC grew its stake in Moderna by 286.2% during the 4th quarter. Venturi Wealth Management LLC now owns 896 shares of the company’s stock worth $37,000 after buying an additional 664 shares during the last quarter. MassMutual Private Wealth & Trust FSB increased its position in Moderna by 58.2% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company’s stock worth $44,000 after buying an additional 389 shares during the period. Finally, Blue Trust Inc. lifted its stake in Moderna by 53.1% in the fourth quarter. Blue Trust Inc. now owns 1,119 shares of the company’s stock valued at $47,000 after buying an additional 388 shares during the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Moderna Stock Down 2.6 %

MRNA opened at $33.81 on Wednesday. The firm has a market cap of $13.04 billion, a PE ratio of -3.64 and a beta of 1.86. The business has a fifty day simple moving average of $35.51 and a 200-day simple moving average of $46.55. Moderna, Inc. has a fifty-two week low of $29.25 and a fifty-two week high of $170.47.

Analyst Upgrades and Downgrades

MRNA has been the subject of several recent research reports. Berenberg Bank upped their price target on shares of Moderna from $33.00 to $42.00 and gave the stock a “hold” rating in a research report on Thursday, January 16th. Morgan Stanley decreased their target price on shares of Moderna from $70.00 to $38.00 and set an “equal weight” rating for the company in a research report on Wednesday, January 15th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $40.00 price target on shares of Moderna in a report on Tuesday, February 18th. Barclays lowered Moderna from an “overweight” rating to an “equal weight” rating and decreased their price objective for the stock from $111.00 to $45.00 in a report on Tuesday, February 18th. Finally, Evercore ISI set a $50.00 target price on Moderna in a research note on Friday, February 14th. Four equities research analysts have rated the stock with a sell rating, sixteen have given a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $59.60.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.